Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase I Study of Ziftomenib as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation

NCT06440135 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT06440135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06440135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase I Study of Ziftomenib as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
June 11, 2024
Completion date
April 1, 2029
Enrollment
22 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, acute myeloid leukemia in remission, kmt2a rearrangement, npm1 mutation